Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panitumumab together with irinotecan may kill more tumor cells.
PURPOSE: This phase II clinical trial is studying giving panitumumab together with irinotecan to see how well it works as third-line therapy in treating patients with metastatic colorectal cancer.

RATIONALE: 单克隆抗体（monoclonal antibodies）如帕尼单抗（panitumumab）可通过多种途径阻断肿瘤生长。部分抗体可抑制肿瘤细胞增殖与扩散的能力；另有部分抗体可识别肿瘤细胞，协助杀伤肿瘤细胞或向其递送杀伤性物质。化疗药物如伊立替康（irinotecan）可通过多种机制抑制肿瘤细胞生长，既可直接杀伤肿瘤细胞，亦可阻止其分裂增殖。联合使用帕尼单抗与伊立替康或可实现更强的肿瘤细胞杀伤效果。
PURPOSE: 本项II期临床试验旨在评估帕尼单抗联合伊立替康作为三线治疗方案，在转移性结直肠癌患者中的临床疗效。